Randomized Trial Links Time of Day to Immunotherapy Success
Abstract
Morning administration of checkpoint inhibitors significantly extended survival in patients with advanced non-small cell lung cancer, in the first randomized trial of immunotherapy timing. The results provide prospective support for aligning treatment with circadian biology as a simple way to improve cancer outcomes.
Fields of Study & Subjects
Cancer Immunotherapy and Biomarkers
Circadian rhythm and melatonin
Lung Cancer Diagnosis and Treatment
Publication details
- Journal / source
- Cancer Discovery
- Volume
- 16
- Issue
- 3
- Pages
- OF1–OF1
- Publication date
- 2 February 2026
- Language
- EN